- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
E-Z-EM to expand Canadian subsidiary
Due to growth in its pharmaceutical and contrast manufacturing business, contrast agent developer E-Z-EM plans to expand the facilities of its Canadian subsidiary, E-Z-EM Canada. The Westbury, NY, company will rent an additional 46,000 square feet
Due to growth in its pharmaceutical and contrast manufacturing business, contrast agent developer E-Z-EM plans to expand the facilities of its Canadian subsidiary, E-Z-EM Canada. The Westbury, NY, company will rent an additional 46,000 square feet adjacent to E-Z-EM Canadas existing 70,000-square-foot facility in Montreal. E-Z-EM Canada will occupy the new site in March, and has the option to lease additional space or buy the facility in the future. E-Z-EM Canada attributed its need for a larger site to increased sales of its major product lines in the past two years, according to Pierre-Andre Ouimet, president.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
